Navigation Links
EntreMed Appoints Senior Vice President of Research and Development
Date:10/16/2007

expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

CONTACT:

Ginny Dunn

Associate Director, Corporate Communications & Investor Relations

EntreMed, Inc.

240.864.264
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... India , July 1, 2015  Strand Life ... generation sequencing technology to empower cancer care, today announced ... chief executive officer. In his expanded role as now ... strategy, business expansion and worldwide operations effective immediately.  Dr. ... chairman and CEO since its founding in 2000, will ...
(Date:7/1/2015)... InferMed , s ... will augment Elsevier ... olutions suite   Elsevier , a world-leading ... announced today the acquisition of  InferMed , a ... InferMed,s Arezzo technology supports clinicians in choosing the most ...
(Date:6/30/2015)... ... June 30, 2015 , ... Students and ... in the first half of “Integrative Biotechnology,” an applied biotechnology course team-taught by ... 2014, this course combines students from both universities and is taught on both ...
(Date:6/30/2015)... 2015  Today, Americord Registry, one of the fastest growing ... , a partner at Kirkland & Ellis LLP, as the ... - http://photos.prnewswire.com/prnh/20150630/226958LOGO   "We are thrilled about ... Martin Smithmyer , CEO of Americord. "He brings a ... will assist Americord,s growth and vision." Andrew ...
Breaking Biology Technology:Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2Americord Registry Announces Andrew Horne as Advisory Board Member 2
... Dallas-based maker of neurotechnology research systems, announced the sale of its ... in 1983. , ... DALLAS (Business Wire EON) ... as it is called by many brain researchers after its inventor, ...
... defects, bulk crystalline materials never achieve their ideal strength; ... no room for defects. ("Nano" is short for nanometer, ... may approach ideal strength in their resistance to stress, ... withstand large internal strains before they fail. Overcoming this ...
... 20 The board of directors,of Eli Lilly and Company ... quarter of 2008 of $0.47 a share on outstanding common ... first three quarters of 2008 and,brings the total annual dividend ... payable December 10, 2008, to shareholders of record at,the close ...
Cached Biology Technology: Plexon Inc Delivers 500th "Harvey Box" : 25 Years of Neural Data Acquisition and Analysis Leads to 500th System Sale 2 Plexon Inc Delivers 500th "Harvey Box" : 25 Years of Neural Data Acquisition and Analysis Leads to 500th System Sale 3Engineering nanoparticles for maximum strength 2Engineering nanoparticles for maximum strength 3Engineering nanoparticles for maximum strength 4
(Date:6/16/2015)... YORK , June 16, 2015  With the ... world, security remains a top concern. The recent compromise ... confirms the need for strong authentication within government agencies. ... Token, a biometric one-time password (OTP) authenticator, has been ... Standards (FIPS) 140-2 Level 3 validation for tamper proofing. ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint ... previously communicated that it will amount to at least 340 ... Due to the rapid increase in market growth and orders ... previously communicated guidance that revenue for 2015 will exceed 1,500 ... amount to approximately 2,200 MSEK. Due to receipt ...
(Date:6/15/2015)... , June 15, 2015 A new ... Telstra reveals the majority of US consumers using mobile banking ... biometrics, such as fingerprint and voiceprint, instead of having to ... According to Telstra,s " Mobile Identity   -   The ... report, with smartphones now the primary channel used by Gen ...
Breaking Biology News(10 mins):Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4
... to $10.3 million to help develop a new prosthetic arm that ... work is a key part of a U.S. Department of Defense ... for soldiers and potentially others whose arms were amputated. , "Imagine ... that allows you to feel both the outside world and your ...
... as saccharin with a sensory experience in which ... guided researchers to an increased understanding of how ... in an advance online publication in Nature, scientists ... certain artificial sweeteners, including sodium saccharin and acesulfame-K, ...
... to how bacteria that infect humans develop a resistance ... January 20 issue of the journal Science, McMaster University ... may be the key in identifying how and why ... future clinical problems, and testing new antibiotics. , Antibiotic ...
Cached Biology News:University of Utah to help build bionic arm 2University of Utah to help build bionic arm 3University of Utah to help build bionic arm 4University of Utah to help build bionic arm 5Sweet 'water taste' paradoxically predicts sweet taste inhibitors 2Researchers use dirt to stay one step ahead of antibiotic resistance 2Researchers use dirt to stay one step ahead of antibiotic resistance 3
... a recombinant protein that has been shown to ... preparation of cDNA by reverse transcription, in vitro ... RNA Safe Inhibitor tightly binds RNases in a ... eukaryotic RNases such as RNase A, RNase B, ...
... Natural and Recombinant RNasin Ribonuclease Inhibitors have ... inhibition of eukaryotic RNases of the neutral ... inhibitory effect by noncovalently binding to RNases ... for the binding of RNasin Ribonuclease Inhibitor ...
...
Canine Aortic Smooth Muscle Cells (CnAOSMC) (>500,000 cells)...
Biology Products: